Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vafidemstat

            Therapeutic Area: Psychiatry/Psychology Product Name: ORY-2001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 06, 2020

            Details:

            ORYZON has presented the final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020, Results demostrate that Vafidemstat reduces aggression in the three psychiatric disorders studied.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vafidemstat

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Spanish Ministry of Science and Innovation

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Funding June 15, 2020

            Details:

            Oryzon's project “VENCER: Vafidemstat Efficacy in the treatment against Schizophrenia and other related pathologies has been approved for funding by the Spanish Ministry of Science and Innovation under the 2019 call of the governmental R&D “RETOS-COLABORACION” program.